U.S. Software Stock News

NasdaqGS:AXTI
NasdaqGS:AXTISemiconductor

AXT (AXTI) Pulls Back After A Strong Run, Is The Stock Still Cheap?

AXT (AXTI) draws fresh attention after recent share price moves, with the stock last closing at US$60.61. Investors are weighing this level against the company’s fundamentals and recent return profile. Over the past year AXT has delivered very large total shareholder returns, with the 1-year total shareholder return more than 10 times higher, even though the share price return over the last 90 days is down 43.2% and recent 7-day trading also shows weaker momentum. Compare AXT's sharp moves...
NYSE:DAL
NYSE:DALAirlines

Delta Air Lines (DAL) Shares Dropped, So What Is Driving Attention Now?

Delta Air Lines (DAL) has drawn fresh attention after recent share price weakness, with the stock down about 11% over the past month and roughly 3% over the past 3 months. Set against that recent pullback, Delta Air Lines still shows a 12.95% year to date share price return and a 27.63% total shareholder return over the past year, which may indicate longer term strength even as shorter term sentiment has cooled. Scan beyond Delta Air Lines and compare its recent pullback with hand picked 45...
NYSE:RNG
NYSE:RNGSoftware

How Investors May Respond To RingCentral (RNG) Expanding AI Communications Reach In New Zealand

Digital Island recently announced it had entered into a partnership with RingCentral to bring RingCentral’s AI-powered Unified Communications, Contact Centre, and customer engagement solutions to businesses across New Zealand, with early-adopter clients already testing the offerings ahead of broader rollout. This collaboration effectively extends RingCentral’s Agentic Voice AI and cloud communications footprint into a new geography, deepening its presence in international enterprise and SME...
NasdaqGS:DXCM
NasdaqGS:DXCMMedical Equipment

G7 Momentum and Global Reach Might Change The Case For Investing In DexCom (DXCM)

In the past quarter, DexCom, Inc. reported that new G6 and G7 continuous glucose monitoring systems, together with broader international distribution, helped support solid operational performance despite ongoing competition. An interesting angle for investors is how DexCom’s expanding global footprint and upgraded product lineup are working together to reinforce its recurring revenue model and operating efficiency. We’ll now explore how DexCom’s latest G6 and G7 product momentum could...
NasdaqGS:EXLS
NasdaqGS:EXLSProfessional Services

Should ExlService’s New US$1 Billion Credit Package Reshape How EXLS Investors View Its Growth Playbook?

On August 18, 2026, ExlService Holdings entered into a new US$600,000,000 revolving credit facility and US$400,000,000 term loan maturing in 2031, using the proceeds to fully repay its prior Citibank credit agreement without prepayment penalties. This larger, longer-dated and covenant-based financing package gives ExlService substantially more committed liquidity and flexibility for acquisitions and other corporate initiatives while keeping leverage within defined limits. We’ll now examine...
NasdaqCM:NNE
NasdaqCM:NNEElectrical

Will AI Data Center Deal With Tillman Shift NANO Nuclear Energy's (NNE) Narrative on Microreactors?

NANO Nuclear Energy Inc. previously announced a non-binding Strategic Commercial Framework with Tillman Global Holdings and Tillman Digital Gateway to position its KRONOS microreactors as the anticipated preferred nuclear technology for future AI-focused U.S. data-center zones, targeting 2 gigawatts of advanced nuclear capacity by the mid-2030s and 6 gigawatts by 2040, subject to multiple approvals and agreements. The framework’s milestone-based warrants and US$5 million restricted stock...
NYSE:HRL
NYSE:HRLFood

Why Hormel (HRL) Is Down 9.3% After Cutting 2026 Guidance And Naming a New CFO

Hormel Foods recently lowered its full-year 2026 guidance, now expecting net sales of about US$12.10–US$12.20 billion and diluted EPS of US$1.06–US$1.12 after reporting weaker third-quarter results with net income of US$59.57 million, down sharply from last year. Beyond the earnings setback, Hormel announced a new CFO with extensive experience in transforming food businesses and highlighted brand activity such as the SPAM Dog launch, underscoring concurrent leadership change and product...
NasdaqGS:SKWD
NasdaqGS:SKWDInsurance

What Is Drawing Attention To Skyward Specialty Insurance Group (SKWD)?

What Skyward Specialty Insurance Group’s CFO transition means for investors Skyward Specialty Insurance Group (SKWD) has outlined a planned finance leadership transition, with long serving CFO Mark Haushill set to retire in March 2027 and Deputy CFO Taryn McHarg stepping into the role. Investors now have a clear timetable for change at the top of the finance function, along with continuity through Haushill’s Senior Advisor role that extends to the end of 2027. Against this planned CFO...
NasdaqGS:XRAY
NasdaqGS:XRAYMedical Equipment

DENTSPLY SIRONA (XRAY) Could Be 17% Undervalued As Margin Repair Comes Into Focus

DENTSPLY SIRONA (XRAY) has drawn investor attention after a period of mixed share performance, with the stock up over the past 3 months but down over the past month and past year. At the current share price of US$11.17, DENTSPLY SIRONA has seen short term momentum pick up, with a 7 day share price return of 2.57%. However, the 1 year total shareholder return is down 19.72%, which points to fading longer term sentiment and an ongoing reassessment of risk and growth potential. Compare DENTSPLY...
NasdaqGS:CLMT
NasdaqGS:CLMTOil and Gas

Is Calumet (CLMT) Fully Priced On Balance Sheet Risks?

Balance sheet worries move into focus for Calumet stock Recent commentary on Calumet (CLMT) has focused on high extraction costs, weaker asset economics, thin margins, and sizeable debt. These issues have raised fresh questions about future funding and the potential need for equity issuance. Despite these balance sheet concerns, Calumet’s share price has been strong, with a 1 month share price return of 12.54%, a 3 month share price return of 37.72%, and a 154.37% year to date share price...
NasdaqGS:WDC
NasdaqGS:WDCTech

Elite Quantum Stocks To Own In September 2026

With central banks sounding more hawkish on inflation and rate hikes, investors are paying closer attention to technologies that could reshape computing power and data analysis over the long term. Quantum computing stocks tap into this theme by targeting hardware, software, and research that aim to tackle complex problems traditional systems struggle to handle. This article highlights three companies from our quantum computing screener to watch now. The stocks covered below are just a small...
NYSE:NET
NYSE:NETIT

Is Cloudflare’s (NET) New Adaptive Intelligence Shaping a Defensible Edge in Bot Security?

Cloudflare, Inc. recently launched Adaptive Intelligence, a continuous AI-driven detection engine embedded in Cloudflare Bot Management that analyzes over a trillion daily web visits to generate short-lived rules against evolving automated cyberattacks. By combining live global edge telemetry with browser-level behavior signals to constantly refine defenses, Adaptive Intelligence aims to make automated attacks significantly more costly and complex for threat actors. We’ll now examine how...
NasdaqGS:FROG
NasdaqGS:FROGSoftware

JFrog (FROG) Security Fix Puts Valuation Back In Focus

Why JFrog Stock Is Back in Focus After a High Profile Security Fix JFrog (FROG) is drawing fresh attention after it patched a critical vulnerability in its Artifactory platform, just as industry voices highlight how AI driven hacking tools could pressure traditional security approaches. That security fix has arrived as JFrog’s stock has picked up strong momentum, with the 1 month share price return of 25.42% and the year to date share price return of 67.99% helping lift the 1 year total...
NasdaqGM:ETON
NasdaqGM:ETONPharmaceuticals

Eton Pharmaceuticals (ETON) Faces A Valuation Test Following Its Rare Disease Growth Narrative

Eton Pharmaceuticals (ETON) stock has drawn investor attention after recent trading, with year to date and past 1 year total returns well above 200%. The move raises questions about how current pricing aligns with fundamentals. At a share price of $60.44, Eton Pharmaceuticals has seen sharp moves over different periods, with a 30 day share price return of 30.20% and a 90 day share price return of 118.91%. The 1 year total shareholder return of 251.60%, along with very large 3 year and 5 year...
NYSE:XIFR
NYSE:XIFRRenewable Energy

XPLR Infrastructure (XIFR) Rebounds In Focus, Is A 94% Undervalued View Justified?

Recent performance snapshot for XPLR Infrastructure XPLR Infrastructure (XIFR) has drawn fresh attention after its rebrand from NextEra Energy Partners in January 2025. The stock last closed at US$12. Recent returns show mixed moves across shorter and longer periods. Over the past year, XPLR Infrastructure has seen share price momentum pick up recently, with a 7 day share price return of 6.3% and a year to date share price return of 18.0%, although the 3 year total shareholder return is still...
NYSE:MWA
NYSE:MWAMachinery

Is Mueller Water Products (MWA) Undervalued As Margin Gains Come Into Focus?

Why Mueller Water Products Stock Is Back On Investors’ Radar Mueller Water Products (MWA) is drawing fresh attention after recent coverage highlighted its profitable earnings growth, stronger operating efficiency, and wider free cash flow margin, prompting investors to reassess the stock’s current valuation. Despite the recent focus on improving profitability, Mueller Water Products’ share price has softened in the near term, with a 7 day share price return of 4.02% lower and a 30 day share...
NYSE:LXP
NYSE:LXPIndustrial REITs

Is LXP Industrial Trust (LXP) Fully Valued Or Still Cheap After Its Strong Run?

LXP Industrial Trust at a Glance LXP Industrial Trust (LXP) is a US real estate investment trust focused on Class A warehouse and distribution assets across 12 target markets. The stock last closed at $60.71, with a market value of about $3.6b. Recent trading has been relatively steady for LXP Industrial Trust, with a 90-day share price return of 20.53% and a year-to-date share price return of 22.45%. The 1-year total shareholder return of 41.57% points to momentum that has been building...
NasdaqCM:CELC
NasdaqCM:CELCBiotechs

How Investors May Respond To Celcuity (CELC) sNDA For REVTORPYK In PIK3CA-Mutant Breast Cancer

In August 2026, Celcuity Inc. announced it had submitted a supplemental New Drug Application to the FDA for REVTORPYK (gedatolisib) to treat HR+/HER2- advanced or metastatic breast cancer with a PIK3CA mutation, based on Phase 3 VIKTORIA-1 data showing improved progression-free survival versus alpelisib plus fulvestrant. If approved, REVTORPYK would become the first therapy for PIK3CA-mutant advanced breast cancer that targets all class I PI3K isoforms and both mTOR complexes, potentially...
NasdaqGS:NSSC
NasdaqGS:NSSCElectronic

Should Napco’s Dividend Hike, Buyback Completion, and M&A Interest Require Action From Napco Security (NSSC) Investors?

In August 2026, Napco Security Technologies reported higher fourth-quarter and full-year revenue and earnings per share, raised its quarterly dividend to US$0.17, confirmed completion of a US$16.15 million buyback program, and indicated it is open to acquisitions if the right opportunity emerges. An interesting angle is that Napco is signaling confidence by simultaneously increasing cash returns to shareholders and keeping its balance sheet ready for its first acquisition in about 17–18...
NasdaqGS:EXTR
NasdaqGS:EXTRCommunications

How Investors Are Reacting To Extreme Networks (EXTR) Switching Auditors From Grant Thornton To Deloitte

In August 2026, Extreme Networks’ audit committee dismissed Grant Thornton LLP and appointed Deloitte & Touche LLP as its independent registered public accounting firm for the fiscal year ending June 30, 2027, and related interim periods. This shift to a Big Four auditor has sharpened attention on the company’s financial reporting controls and refreshed debate around its longer-term valuation story. We’ll now examine how the move to Deloitte as auditor could influence Extreme Networks’...
NYSE:CBU
NYSE:CBUBanks

Community Financial System (CBU) Faces A Pullback As Valuation Signals Stay Mixed

Community Financial System at a glance Community Financial System (CBU) operates as a diversified financial services company through banking, employee benefit, insurance, and wealth management segments, serving retail, commercial, institutional, and governmental customers in the United States. The company reports US$838.2m in revenue and US$229.0m in net income. Its Banking and Corporate segment contributes the largest portion of revenue, alongside meaningful contributions from employee...
NYSE:SPG
NYSE:SPGRetail REITs

Simon Property Group (SPG) Unveils A New Ad Business Inside Its Retail Footprint

Simon Property Group (NYSE: SPG) has launched Simon Media Network, a commerce media platform for advertisers across its retail destinations. The new offering uses shopper and location data from Simon properties to support targeted, data driven campaigns for brands. Simon Media Network is designed to create new advertising revenue streams while adding marketing capabilities for tenants and partners. To put Simon Property Group in context, consider exploring other income focused stocks in...
NasdaqGS:FIVE
NasdaqGS:FIVESpecialty Retail

How Investors May Respond To Five Below (FIVE) After Zacks Highlights Its Earnings Growth Potential

Recently, analyst firm Zacks highlighted Five Below as a strong growth stock, citing its favorable Growth Score, top Zacks Rank, and earnings estimates that are projected to outpace the broader industry. This coverage underscores how positive revisions to earnings expectations can influence investor perception of Five Below’s growth profile and business momentum. Next, we’ll explore how this upbeat analyst commentary on earnings growth and estimate revisions may reshape Five Below’s broader...
NasdaqGS:HALO
NasdaqGS:HALOBiotechs

How Investors Are Reacting To Halozyme Therapeutics (HALO) Adding Dealmaker Appelhans To Bolster ENHANZE Partnerships

In August 2026, Halozyme Therapeutics appointed Dannielle Appelhans, an executive with more than 20 years of biotech and pharma leadership in operations, manufacturing, and supply chain, to its Board of Directors. Her track record leading complex manufacturing organizations and negotiating large-scale pharma collaborations, including a potential US$1.00 billion deal at COUR Pharmaceuticals, may strengthen Halozyme’s efforts to scale its ENHANZE-based partnerships. With this new operational...